BioWorld Asia

May 6, 2009

Report: Global Funding Crisis Endangering Biotech Model

LONDON - The global financial crisis is making the biotech business model unsustainable, says the consultancy Ernst and Young in its 23rd annual report on the industry. (BioWorld International) Read More

UK's Biotech Problems Bemoaned at Conference

Resequencing Study May Lead to Better Genetic Counseling

Vernalis Raises £22M Offering Hefty Discount

BioXell Shares Plunge on Elocalcitol Miss

Circ, Elan Partner on Pain Drug Formulation

Cerep and PerkinElmer Expand Assay Offering

Pharmaxis Hits the Mark in Phase III Cystic Fibrosis Trial

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Dec. 24, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 24, 2025.

Illustration of magnifying glass looking at cancer in the brain

Researchers discover how glioblastoma tumors dodge chemotherapy

BioWorld MedTech

Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...

Left: Anthony Fauci. Right: Transmission electron micrograph of HIV-1 virus particles

HIV research is close to a cure but far from ending the pandemic

BioWorld

Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...

Illustration of tau accumulating in a neuron cell.

ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug

BioWorld

ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...